-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The addition of cytotoxic chemotherapy to immune checkpoint inhibitor (ICI) therapy may enhance antitumor effects
Taniguchi et al.
The primary endpoint of the phase III study portion was overall survival (OS), and secondary endpoints included progression-free survival (PF), overall response rate (ORR), and toxicity
Overall survival in both groups
A total of 128 patients (64 in each group) were included in the overall analysis cohort (FAS)
Hematological and gastrointestinal adverse events were more common in arm
In conclusion, the addition of docetaxel to nivolumab significantly prolonged OS and PFS in previously ICI-naïve NSCLC patients despite a slight increase in toxicity
Original source:
Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.